Plain-English translation of NCT06636435 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Solid Tumors research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human trial testing a new medication called CBA-1205, which is designed to target a specific protein involved in cancer growth. The study is enrolling about 66 patients with advanced cancers—including liver cancer, melanoma, and pediatric cancers—who have either exhausted standard treatment options or cannot tolerate them. Researchers will carefully evaluate whether the medication is safe and whether it helps slow or stop cancer growth.
Many patients with advanced cancers run out of effective treatment options, or the standard treatments become too toxic to continue. This trial exists to see if this new medication could offer another chance for patients who have limited alternatives.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous injections of the medication every 2 weeks, with each treatment cycle lasting 28 days. The study involves multiple parts testing different dose levels and different cancer types, so your specific schedule and duration would depend on which part you enroll in and how well you tolerate the treatment. You would continue receiving the medication until either you experience unacceptable side effects, your cancer progresses significantly, or the research team determines it is no longer beneficial.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
Japan